---
layout: default
title: Alpha -Tocopherol Ascorbic Acid Beta Carotene Chol
parent: 僅模型預測 (L5)
nav_order: 239
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Ascorbic Acid Beta Carotene Chol
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Supplement Complex: Repurposing Evaluation Not Feasible

## One-Sentence Summary

This submission contains a complex multi-ingredient formula comprising 14 components — including vitamins, antioxidants, cycloastragenol, and biological extracts such as herring sperm DNA and porcine posterior pituitary gland.
The TxGNN model was **unable to generate any repurposing predictions** because the compound string could not be resolved to a single drug entity in the knowledge graph.
With **0 clinical trials**, **0 publications**, and **0 regulatory licenses** retrieved, this case cannot proceed to standard repurposing evaluation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no regulatory record found) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — but no prediction was generated) |
| Market Status | Not Marketed |
| Number of Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The drug identifier submitted to the pipeline is not a single chemical entity but a semicolon-separated list of 14 distinct ingredients:

> α-Tocopherol · Ascorbic Acid · Beta-Carotene · Cholecalciferol · Cyanocobalamin · Cycloastragenol · Glutathione · Herring Sperm DNA · Omega-3 Fatty Acids · Pantothenic Acid · Riboflavin · Saccharomyces Cerevisiae RNA · Sus Scrofa Pituitary Gland (Posterior) · Thiamine

TxGNN operates on individual DrugBank-mapped entities. Because this compound string could not be resolved to a DrugBank ID, the knowledge graph traversal and deep learning scoring steps were both skipped. As a result, `predicted_indications` is empty and no downstream evidence collection (clinical trials, literature) was triggered.

Additionally:
- No regulatory record was found in the database (0 licenses).
- No DrugBank ID was matched, blocking MOA retrieval.
- The combination includes non-pharmaceutical biological materials (herring sperm DNA, porcine pituitary gland extract) that fall outside standard drug ontologies.

---

## Safety Considerations

Please refer to the product label or package insert for safety information. No drug interaction data, warnings, or contraindication records were retrieved for this multi-ingredient submission.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The submission could not be processed because TxGNN requires a single, DrugBank-resolvable active ingredient. A 14-component formula submitted as a concatenated string is outside the model's input specification, yielding zero predictions and zero evidence.

**To proceed, the following is needed:**

1. **Decompose the formula** — Submit each active ingredient individually (e.g., Cycloastragenol alone, Omega-3 Fatty Acids alone) to generate per-component TxGNN predictions.
2. **Identify the primary active ingredient** — If there is one ingredient driving the therapeutic hypothesis (e.g., Cycloastragenol for telomere biology), prioritize that candidate for a dedicated Evidence Pack.
3. **Clarify the product category** — Determine whether this product is regulated as a pharmaceutical drug, dietary supplement, or biological extract. If it is a nutraceutical or food supplement, standard drug repurposing methodology does not directly apply.
4. **Obtain a DrugBank ID** for each component to enable knowledge graph mapping.
5. **Retrieve the product label** — If this product was submitted to any regulatory agency, obtain the original product monograph to establish the intended indication and safety profile.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

